Dr Michael Green: Further Research Is Needed to Better Understand CAR T-Cell Exhaustion

Video

Chimeric antigen receptor (CAR) T-cell exhaustion likely stems from chemotherapy prior to transplant, noted Michael R. Green, PhD, University of Texas MD Anderson Cancer Center.

Chimeric antigen receptor (CAR) T-cell exhaustion likely stems from patients undergoing several rounds of chemotherapy prior to transplant, noted Michael R. Green, PhD, associate professor of lymphoma and myeloma and director, Translational and Laboratory Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center.

Transcript

How will you continue to investigate CAR T-cell exhaustion in patients with diffuse large B-cell lymphoma?

I think one thing that we've become interested in as a result of the study is really understanding the origin and nature of T-cell exhaustion that we've observed in the infusion products. Our hypothesis is that this probably originates from the apheresis product and is a consequence of these patients being highly pretreated, undergoing going several rounds of chemotherapy, because they're a highly refractory and relapsed population.

So I would like to understand more about the factors that that lead to CAR T-cell exhaustion, so that we can hopefully address them either during manufacturing or maybe selecting patients better for autologous products, maybe selecting out patients that may benefit more from an allogeneic product, [which] are currently looking good in clinical trials.

There's several lines of questioning around the origin nature of CAR T-cell exhaustion or T-cell exhaustion generally.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Sven Moller-Tank, PhD, a senior director at Regeneron
Alexey Danilov, MD, PhD, the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, codirector of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Related Content
© 2025 MJH Life Sciences

All rights reserved.